Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $2.14 USD
Change Today +0.11 / 5.42%
Volume 87.8K
BIOL On Other Exchanges
As of 8:10 PM 05/1/15 All times are local (Market data is delayed by at least 15 minutes).

biolase inc (BIOL) Snapshot

Previous Close
Day High
Day Low
52 Week High
12/5/14 - $3.00
52 Week Low
05/14/14 - $1.69
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for BIOLASE INC (BIOL)

Related News

No related news articles were found.

biolase inc (BIOL) Related Businessweek News

No Related Businessweek News Found

biolase inc (BIOL) Details

BIOLASE, Inc., a medical device company, develops, manufactures, and markets laser systems in dentistry and medicine in the Unites States and internationally. It offers Waterlase dental laser systems for cutting soft and hard tissue; and diode laser systems, which are used in soft tissue, pain therapy, and cosmetic procedures, such as teeth whitening. The company’s dental laser systems allow dentists, periodontists, endodontists, oral surgeons, and other dental specialists to perform a range of dental procedures, including cosmetic, restorative, and complex surgical applications. It also markets and distributes dental imaging equipment, including cone beam digital X-rays and CAD/CAM intra-oral scanners, and in-office, chair-side milling machines and three-dimensional (3-D) printers, as well as provides precision intuitive diagnosis and treatment planning solutions. The company’s dental imaging products comprise 3Shape Trios CAD/CAM digital impression systems, which are spray-free scanning devices; Galaxy BioMill CAD/CAM system that enables dental practitioners to complete scanning, designing, milling, and finishing of crowns, inlays, and veneers in the dental office; and 3-D printers that allow dentists to fabricate stone models, orthodontic appliances, delivery and positioning trays, models for clear aligners, retainers, and surgical guides on their desktop. In addition, it manufactures and sells consumable products and accessories for its laser systems, as well as markets flexible fibers and hand pieces. The company sells its products primarily to dentists in general practice through its direct sales force and distributor network. BIOLASE, Inc. has a strategic agreement with Valam, Inc. to develop, market, and sell office-based laser systems to otolaryngologists. The company was formerly known as BIOLASE Technology, Inc. and changed its name to BIOLASE, Inc. in 2012. BIOLASE, Inc. was founded in 1984 and is headquartered in Irvine, California.

210 Employees
Last Reported Date: 03/6/15
Founded in 1984

biolase inc (BIOL) Top Compensated Officers

Chief Executive Officer, President, Director ...
Total Annual Compensation: $150.0K
Vice President of Research and Development
Total Annual Compensation: $250.0K
Director of Professional Relations
Total Annual Compensation: $90.0K
Compensation as of Fiscal Year 2014.

biolase inc (BIOL) Key Developments

BIOLASE, Inc. Reports Unaudited Consolidated Earnings Results for the First Quarter Ended March 31, 2015

BIOLASE, Inc. reported unaudited consolidated earnings results for the first quarter ended March 31, 2015. For the quarter, the company reported net revenue of $10.751 million as compared to $11.479 million for first quarter of 2014. The quarter-over-quarter decrease in revenue was principally due to a decline in worldwide imaging revenue and approximately $600,000 resulting from the negative impact of foreign currency exchange rate fluctuations, partially offset by increases in revenue from consumables, license fees and royalties. Net loss was $5.436 million or $0.09 per diluted share as compared to $4.887 or $0.13 per diluted share million in 2014. The year-over-year increase in net loss was primarily due to lower gross profit of $731,000 in the 2015 first quarter partially offset by lower total operating expenses of $107,000, for the reasons explained above. Adjusted Non-GAAP net Loss for this year’s first quarter totaled $4.5 million, or a loss of $0.08 per basic and diluted share, compared with a non-GAAP net loss of $4.1 million, or $0.11 per basic and diluted share, during the prior year first quarter. The company reported loss from operations of $5.259 million compared to $4.635 million and loss before income tax provision of $5.389 million compared to $4.863 million for the last year.

BIOLASE, Inc. Ratifies Amendment to Bylaws

BIOLASE, Inc. annual meeting of stockholders held on April 27, 2015, stockholders ratified the amendment to the company's Bylaws, as previously approved by the Board of Directors.

BIOLASE, Inc. to Report Q1, 2015 Results on Apr 30, 2015

BIOLASE, Inc. announced that they will report Q1, 2015 results at 4:05 PM, US Eastern Standard Time on Apr 30, 2015


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
BIOL:US $2.14 USD +0.11

BIOL Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Bacterin International Holdings Inc $4.25 USD +0.05
Cogentix Medical Inc $1.61 USD +0.026
Cutera Inc $13.88 USD +0.26
Cytori Therapeutics Inc $0.87 USD -0.0098
Stereotaxis Inc $1.91 USD +0.01
View Industry Companies

Industry Analysis


Industry Average

Valuation BIOL Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 2.4x
Price/Book 3.0x
Price/Cash Flow NM Not Meaningful
TEV/Sales 2.0x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact BIOLASE INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at